Table 4.
Univariable and multivariable Cox regression analysis for stage I NSCLC patients in the propensity score matched cohort who underwent lobectomy with SND or with SNS or SLNB.
| Overall survival | Disease-free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Sex | ||||||||
| Female | Reference | Reference | ||||||
| Male | 1.317(0.902–1.924) | <0.154 | 1.071(0.767–1.495) | 0.688 | ||||
| Age(years) | 1.030(1.013–1.048) | 0.001 | 1.025(1.008–1.042) | 0.004 | 1.011(0.996–1.026) | 0.170 | ||
| Histology | ||||||||
| SCC | Reference | Reference | ||||||
| Non-SCC | 0.954(0.655–1.391) | 0.809 | 1.407(0.959–2.063) | 0.081 | ||||
| Differentiation | ||||||||
| Poor–None | Reference | Reference | Reference | |||||
| Well–Moderate | 0.671(0.476–0.944) | 0.022 | 0.685(0.483–0.970) | 0.033 | 0873(0.633–1.203) | 0.406 | ||
| Tumor size(cm) | 1.336(1.110–1.608) | 0.002 | 1.243(0.997–1.550) | 0.053 | 1336(1.130–1.579) | 0.001 | 1.139(0.941–1.379) | 0.182 |
| Smoking history | ||||||||
| No | Reference | Reference | ||||||
| Yes | 1.201(0.849–1.700) | 0.301 | 1.109(0.802–1.532) | 0.532 | ||||
| Pathological stage | ||||||||
| 1A1 | Reference | Reference | Reference | Reference | ||||
| 1A2 | 5.641(0.748–42.538) | 0.093 | 5.061(0.664–38.599) | 0.118 | 2.780(0.639–12.094) | 0.173 | 2.399(0.545–10.557) | 0.247 |
| 1A3 | 4.879(0.641–37.123) | 0.126 | 3.886(0.491–30.786) | 0.199 | 3.194(0.734–13.896) | 0122 | 2.335(0.516–10.569) | 0.271 |
| 1B | 7.968(1.111–57.166) | 0.039 | 5.143(0.674–39.262) | 0.114 | 5.552(1.372–22.471) | 0.016 | 3.868(0.898–16.659) | 0.069 |
| Bronchus invasion | ||||||||
| No | Reference | Reference | ||||||
| Yes | 1.199(0.829–1.735) | 0.334 | 0.896(0.623–1.289) | 0.555 | ||||
| Adjuvant therapy | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 0.415(0.203–0.849) | 0.016 | 0.410 (0.198–0.847) | 0.016 | 0.939(0.574–1.536) | 0.801 | ||
| EGFR mutation | ||||||||
| Negative | Reference | Reference | ||||||
| Positive | 0.414(0.152–1.124) | 0.084 | 1.197(0.666–2.153) | 0.548 | ||||
| ALK mutation | ||||||||
| Negative | Reference | Reference | ||||||
| Positive | 0.917(0.521–1.617) | 0.766 | 1.500(0.357–6.312) | 0.580 | ||||
| LN dissection group | ||||||||
| SND | Reference | Reference | Reference | Reference | ||||
| SNS or SLNB | 1.435(1.003–2.053) | 0.048 | 1.305(1.008–1.877) | 0.050 | 01.546(1.115–2.144) | 0.009 | 1.417(1.020–1.968) | 0.038 |
ALK, anaplastic lymphoma kinase; CI, confidence interval; cm, centimeter; EGFR, epidermal growth factor receptor; HR, hazard ratio; LN, lymph node; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; SLNB, selected lymph node biopsy; SND, systematic nodal dissection; SNS, systematic nodal sampling.